At HALIX, we are dedicated to empowering biotech companies create life-saving therapeutics and deliver them to those in need, enabled by three key strengths:
-
Infrastructure, skill, and discipline of a seasoned company
- Speed, innovation, and dynamism of a startup
- Open, proactive, and agile communication
Over a decade of experience bringing GMP excellence
We are a fast growing, contract development and manufacturing organization (CDMO) focused on mammalian expression systems for the production of viral vectors, viral vector vaccines and recombinant proteins. Located within the Leiden Bio Science Park in the Netherlands, we support our customers develop and bring to market biologics that can be used to treat cancer, COVID-19, influenza, and other life-threatening and infectious diseases.
A solid foundation
Established in 2012 as a spin-off of HAL Allergy — one of the top European pharma players in the field of allergy immunotherapy — we leverage HAL’s years of industry experience and GMP expertise in the extraction, purification and modification of biologics and benefit from a close corporate structure providing long-term stability.
Communication as key to succeed your project
We combine ‘single point of contact’ project management with proven and sound processes and procedures. From development to clinical up to commercialization, we provide high quality and flexible CDMO services to biopharmaceutical partners, enabling you to progress through clinical phases in order to enter and supply your markets with the most efficient use of resources.
Our core values
Serving bioscience is in our DNA. We understand that when our customers entrust us with their products they are entrusting us with something invaluable, so we take excellent care of it, providing them with the utmost reliability.
We are relentless in the creation of life-saving products.
We collaborate openly and transparently with our customers, always acting as a trusted partner.
We recognize the risks associated with clinical trials and commercialization, so we move fast and embrace change to help our customers navigate these challenges and achieve success.
Stability and long-term focus
HALIX was established as an 100% subsidiary of HAL Allergy Holding B. V., internationally known as HAL Allergy Group. The HAL Allergy Group belongs to the family owned Droege Group AG, an independent advisory and investment company under full family ownership. Together with the Droege Group and the HAL Allergy Group, HALIX has two strong corporate partners ensuring financial stability, opportunity investment, and a long term focus.